Kowa Company Limited

Takao Nagoya

Hiroshi Nakao

Makoto Suda

Seiichi Sato

Hiroyuki Ishiwata

Soichi Oda

Mototsugu Kabeya

Manabu Shibasaki

Yukio Hattori

Masami Shiratsuchi

Yushi Saino

Hiromichi Shigyo

Nobuo Aoki

Shigeru Kimura

Hideo Tani

Masahiro Maki

Michihisa Umetani

Diamide compound and medicine containing the same

Cyclic amide compound

Diamide compounds and compositions containing the same

Cyclic amide compounds

Diamide compound and drugs containing the same

The present invention relates to compounds represented by the following general formula (1):

The present invention is directed to a cell adhesion inhibitory agent, cellular infiltration inhibitory agent, antiallergic agent, antiasthmatic agent, and antiphlogistic, which contains a compound of the following formula (1): ##STR1## wherein each of R.sup.1 through R.sup.6 represents H, a halogen atom, a hydroxyl group, a lower alkyl group, or a lower alkoxy group, m represents a number of 1 from 3 inclusive, and n represents 2 or 3.

Inhibitors for cell adhesion and cellular infiltration

Therapeutic agent for skin or corneal disease

A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placenta-derived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologically assayed by using the monoclonal antibodies.

Placenta-derived coagulation inhibitor

Anti-PCI monoclonal antibody

The present invention provides a monoclonal antibody specific to a thrombin-binding substance (TM), hybridomas producing the monoclonal antibody, a purification process of TM featuring the use of the monoclonal antibody as an immunoadsorbent, as well as an immunoassay of TM featuring the use of the monoclonal antibody.

Anti-thrombin-binding substance monoclonal antibodies, hybridomas

Growing community of inventors

Tsuchiura, Japan

Takao Nagoya